CVRx (NASDAQ:CVRX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.33, a high estimate of $22.00, and a low estimate of $14.00. Observing a 20.94% increase, the current average has risen from the previous average price target of $14.33.
Investigating Analyst Ratings: An Elaborate Study
The standing of CVRx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| William Plovanic | Canaccord Genuity | Raises | Buy | $22.00 | $17.00 |
| Alexander Nowak | Craig-Hallum | Raises | Buy | $20.00 | $15.00 |
| Frank Takkinen | Lake Street | Raises | Buy | $15.00 | $12.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $17.00 | $15.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $16.00 | $13.00 |
| Ross Osborn | Cantor Fitzgerald | Maintains | Overweight | $14.00 | $14.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CVRx. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVRx compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CVRx's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVRx's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on CVRx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About CVRx
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Unraveling the Financial Story of CVRx
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: CVRx displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 27.23%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -97.95%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CVRx's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -21.75%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.71%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CVRx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.77.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
